GlassScriptPhysician profile
Jane Y Choi
NPI 1407171051
$2,150.57
in general payments reported to CMS, 2019-2025
27 companies · $63.20 in 2025
The $63.20 reported for 2025 was less than what a typical General Practice (Dentist) provider received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.49 · 2020: $12.43 · 2021: $413 · 2022: $1,178 · 2023: $154 · 2024: $290 · 2025: $63.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acteon INC | $873.00 | 2022 | |
| Puma Biotechnology, INC. | $189.50 | 2021-2025 | |
| Emd Serono, INC. | $153.47 | 2021-2024 | |
| Myovant Sciences INC. | $97.98 | 2021-2022 | |
| Organon LLC | $78.01 | 2021-2023 | Ontruzant |
| Lilly USA, LLC | $66.95 | 2022-2024 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $59.61 | 2022-2024 | Enhertu |
| Taiho Oncology, INC. | $58.93 | 2021 | |
| Janssen Biotech, INC. | $58.30 | 2024 | Darzalex |
| Glaxosmithkline, LLC. | $53.72 | 2024 | Zejula, Jemperli |
| Servier Pharmaceuticals LLC | $51.84 | 2021-2022 | |
| A-Dec, INC. | $51.00 | 2021 | |
| Acrotech Biopharma INC. | $39.83 | 2022 | |
| Rigel Pharmaceuticals, INC. | $39.01 | 2021-2024 | Rezlidhia, Tavalisse |
| Align Technology, INC. | $31.76 | 2023-2025 | Invisalign |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $29.22 | 2020-2025 | Oral Hygieneother |
| E.R. Squibb & Sons, L.L.C. | $27.12 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.80 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $25.60 | 2021 | |
| Henry Schein, INC. | $21.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.44 | 2021 | |
| G1 Therapeutics, INC. | $18.93 | 2022 | |
| Kerr Corporation | $18.16 | 2019 | |
| Merck Sharp & Dohme LLC | $15.96 | 2021 | |
| Dentsply Sirona INC | $15.70 | 2021 | |
| Celgene Corporation | $15.62 | 2021 | |
| Colgate Oral Pharmaceuticals, INC. | $14.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.